Why Mira Shares Are Trading Higher Today
Why Mira Shares Are Trading Higher Today
MIRA Pharmaceuticals remains focused on advancing the development of Ketamir-2 and is planning to submit an Investigational New Drug (IND) application to the FDA by December 2024. The company is aiming to demonstrate the efficacy of Ketamir-2 in humans by 2025, with Phase I/II studies designed to validate its clinical effectiveness in treating neuropathic pain and other neurological conditions. MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) shares closed higher Friday following the announcement of promising new preclinical data for its lead development product, Ketamir-2.
MIRA製藥公司（NASDAQ：MIRA）股價週五收高，因爲該公司宣佈了其領先開發產品Ketamir-2有前景的新臨床前數據。
What To Know: The data, which will be presented at the 18th Annual Pain Therapeutics Summit in Boston this October, shows that Ketamir-2 achieved a 100% reversal of neuropathic pain in preclinical models. Ketamir-2, a novel oral Ketamine analog, selectively targets the PCP site of the NMDA receptor, offering enhanced efficacy with fewer side effects compared to traditional ketamine treatments.
值得了解的是：這一數據將於今年十月在波士頓舉行的第18屆疼痛治療高峰會上進行展示，顯示Ketamir-2在臨床前模型中實現了神經病性疼痛完全逆轉的100%。 Ketamir-2是一種新型口服氯胺酮類似物，選擇性地靶向NMDA受體的PCP位點，相比傳統的氯胺酮治療，效力更高且副作用更少。
Neuropathic pain, often caused by nerve damage or dysfunction, remains a major challenge in pain management due to the limitations of existing therapies and the potential for Ketamir-2 to offer full normalization of pain responses marks a significant advancement. The data will be presented by Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals, at the summit.
神經病性疼痛通常由神經損傷或功能障礙導致，在疼痛管理中仍然是一個重大挑戰，因爲現有療法的侷限性以及Ketamir-2有可能提供完全正常化疼痛反應的潛力標誌着重大進展。這些數據將由MIRA製藥公司的首席科學顧問Itzchak Angel博士在高峰會上進行展示。
MIRA Pharmaceuticals remains focused on advancing the development of Ketamir-2 and is planning to submit an Investigational New Drug (IND) application to the FDA by December 2024. The company is aiming to demonstrate the efficacy of Ketamir-2 in humans by 2025, with Phase I/II studies designed to validate its clinical effectiveness in treating neuropathic pain and other neurological conditions.
MIRA製藥公司仍專注於推進Ketamir-2的開發，並計劃在2024年12月向FDA提交一份新藥探索性申請（IND）。該公司旨在通過2025年在人體中展示Ketamir-2的功效，設計階段I/II研究來驗證其在治療神經病性疼痛和其他神經疾病方面的臨床有效性。
MIRA Price Action: Mira shares closed up 8.41% at $1.16 at the time of writing, according to Benzinga Pro.
MIRA股價走勢：根據Benzinga Pro的數據，Mira股價在撰寫本文時以1.16美元漲幅8.41%收盤。
- China's Tech Stocks Surge: What Top Investors Know That You Don't
- 中國科技股飆升：頂級投資者知道而你卻不知道的事情
Image Via Shutterstock.
圖片來自Shutterstock。
譯文內容由第三人軟體翻譯。
